11:42 PM EDT, 10/08/2026 (MT Newswires) -- Roche's (RO.SW) Genentech unit secured approval from the US Food and Drug Administration for Tecentriq, or atezolizumab, plus chemotherapy as a treatment for stage 3 mismatch repair deficient, or dMMR, colon cancer. According to the Thursday notice, Tecentriq plus chemotherapy is indicated for adult and pediatric patients at least two years. The combination of Tecentriq Hybreza and chemotherapy was also approved as adjuvant treatment for patients with stage 3 dMMR colon cancer aged 12 years and older who weigh 40 kilograms or more. The decision was granted under priority review and was based on the results of the Atomic/ML39057 study, which involved 711 adults and one pediatric patient.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.